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Zika virus (ZIKV) is a mosquito-transmitted Flavivirus, originally identified in Uganda in 1947 and 
recently associated with a large outbreak in South America. Despite extensive efforts there are 
currently no approved antiviral compounds for treatment of ZIKV infection. Here we describe the 
antiviral activity of diarylamines derived from anthranilic acid (FAMs) against ZIKV. A synthetic FAM 
(E3) demonstrated anti-ZIKV potential by reducing viral replication up to 86%. We analyzed the 
possible mechanisms of action of FAM E3 by evaluating the intercalation of this compound into the viral 
dsRNA and its interaction with the RNA polymerase of bacteriophage SP6. However, FAM E3 did not 
act by these mechanisms. In silico results predicted that FAM E3 might bind to the ZIKV NS3 helicase 
suggesting that this protein could be one possible target of this compound. To test this, the thermal 
stability and the ATPase activity of the ZIKV NS3 helicase domain (NS3Hel) were investigated in vitro and 
we demonstrated that FAM E3 could indeed bind to and stabilize NS3Hel.
Zika virus (ZIKV) is a mosquito - transmitted virus first isolated in 1947 from a Rhesus monkey in the Zika forest, 
Uganda1. ZIKV remained endemic to the African and Asian regions until 2007, since then the virus has spread to 
other continents2–6. Notably, in 2015, the ZIKV outbreak had a worldwide impact and was considered a serious 
public health problem due to the large number of people infected and the development of neurological disorders 
in neonates (microcephaly) and adults (Guillain Barre syndrome)7.
Similar to other arboviruses such as Dengue virus (DENV), Yellow Fever virus (YFV) and Chikungunya virus 
(CHIKV), ZIKV is mainly transmitted by Aedes spp. of mosquitoes8–10. Nevertheless, other sources of infec-
tion acquisition have been reported, including blood transfusion9, sexual11,12, perinatal and transplacental trans-
missions5,13. Recently, it has been suggested that ZIKV may also have a sylvatic transmission cycle which could 
increase the frequency of human reinfection14.
ZIKV belongs to the Flaviviridae family and genus Flavivirus15. As other members of the genus, the viral 
genome is a positive single-stranded RNA with one open reading frame (ORF), translated in a polyprotein that is 
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cleaved by host and viral proteases into 10 proteins. The polyprotein yields seven nonstructural proteins involved 
in the viral replication process (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5), and three structural proteins 
(capsid (C), pre-membrane (prM) and the envelope (E) proteins), which comprise the viral particles16–18.
There are currently no approved antiviral compounds targeting ZIKV infection. The treatment of infected 
individuals is palliative and consists of fluid intake and rest. Therefore, there is an urgent need for research to 
develop effective antivirals. In this context, the therapeutic properties of natural compounds have been histori-
cally described for the treatment of several viral diseases, such as hepatitis C virus (HCV)19,20, human immuno-
deficiency virus (HIV-1)21, CHIKV22, DENV and West Nile virus (WNV)23. Natural products present advantages 
such as high chemical diversity, low cost of production and efficient metabolism24,25. However, compounds 
isolated from natural sources are not patentable and the isolation process is time consuming24,26. An attractive 
alternative is to use the structure of the natural products as scaffolds for the synthesis of new molecules that can 
enhance the bioactivity and are more amenable to large scale manufacture26–28.
Natural and synthetic acids have attracted attention due to their potent antiviral properties. This is exemplified by 
glycyrrhizic acid which prevents the release of HCV infectious particles29 and inhibits hepatitis A virus (HAV) penetra-
tion into the host cell30, and 3,5-dicaffeoylquinic acid, 1-methoxyoxalyl-3,5-dicaffeoylquinic acid, and L-chicoric acid 
that were described to prevent HIV-1 viral replication31. Similarly, nordihydroguaiaretic acid (NDGA) and its derivative 
tetra-o-methyl nordihydroguaiaretic acid were demonstrated to block DENV, HCV32, WNV and ZIKV33 replication.
Here we evaluated the antiviral activity of synthetic diarylamines derived from anthranilic acid (FAMs) on 
ZIKV infection in vitro and in silico. Our data showed that FAM E3 significantly inhibited the ZIKV genome 
replication.
Results
ZIKV infection can be inhibited by synthetic FAMs. A panel of FAMs synthesized based on natural 
scaffolds was screened using a recombinant ZIKV that expresses the Nanoluciferase reporter (ZIKV-Nanoluc) 
(Fig. 1A). This recombinant virus was shown previously to exhibit a similar replication rate to wild type virus34. 
To assess cytotoxicity, Vero cells were treated with differing concentrations of each FAM (0.4, 2, 10 and 50 μM) 
and cell viability was measured 72 h post-treatment. Then, Vero cells were infected with ZIKV-Nanoluc at a MOI 
of 0.1 in the presence or absence of each compound at specific concentrations and Nanoluciferase activity levels, 
proportional to viral replication, were assessed 72 h post infection (h.p.i).
From all compounds evaluated, FAM E3 (Fig. 1B) showed the highest inhibition rate (Table S1). We therefore 
performed a dose response assay to determine effective concentration 50% (EC50) and cytotoxicity 50% (CC50) 
values for FAM E3. ZIKV-Nanoluc infected Vero cells were therefore treated with FAM E3 at concentrations rang-
ing from 1 to 10 µM and virus replication efficiency was evaluated 72 h.p.i. In parallel cell viability was measured 
by MTT assay. Our data showed that FAM E3 was able to inhibit >99% of virus replication, while the minimum 
cell viability remained above 60% (Fig. 1C). Using a wider range of FAM E3 concentrations, it was determined 
that the compound has an EC50 of 2.59 µM, CC50 of 8.0 µM and SI of ~3 (Fig. 1D). For further analysis, cells were 
treated with FAM E3 at 3 µM, which inhibited approximately 96% of ZIKV infectivity with cell viability >88% 
(Fig. 1C). To confirm that the activitiy of FAM E3 against ZIKV was not specific to the laboratory isolate, it was 
also tested against a primary clinical isolate of ZIKV (provided by the Evandro Chagas Institute in Belém, Pará35) 
(ZIKVBR). For this, Vero cells were infected with ZIKVBR at MOI = 0.1 and treated with FAM E3 3 µM or controls 
for 72 h. Then, intracellular virus was titrated by analysing focus-forming units per milliliters (Ffu/mL). The 
results corroborated to the data from ZIKV-Nanoluc (Fig. 1E).
The antiviral effect of FAM E3 was also investigated in the ZIKV human permissive cell lines Huh-7 and 293 T. 
Infected cells were treated with 3 µM of FAM E3 and both cell viability and ZIKV infectivity were evaluated. The 
results showed that FAM E3 was able to significantly decrease ZIKV replication levels in both cell types (Fig. 1F). 
However, 293 T cells appeared to be acutely sensitive to the cytotoxic effect of FAM E3.
FAM E3 inhibits the post-entry stage of ZIKV replication. To analyze the effects of FAM E3 on dif-
ferent stages of the ZIKV replicative cycle, time of addition experiments were performed. To evaluate the activity 
of compound on virus entry, FAM E3 and ZIKV-Nanoluc were simultaneously added to the cells for 2 h at 37 °C. 
Then, the inoculum was removed, cells were extensively washed with PBS, fresh media was added, and the cells 
were incubated for 72 h (Fig. 2A). In contrast to the control obatoclax (OLX) that is known to inhibit the entry of 
ZIKV36, the results showed that FAM E3 had no effect on ZIKV entry into the host cell (Fig. 2A).
We further investigated whether FAM E3 could elicit a protective effect. For this, cells were pretreated by incu-
bation in medium containing FAM E3 for 2 h. prior to infection with ZIKV-Nanoluc for 72 h as shown in Fig. 2B, 
FAM E3 had no significant effect on ZIKV infection, suggesting that this compound is not acting by rendering the 
cells refractory to infection with ZIKV (Fig. 2B).
Finally, we analyzed the effect of FAM E3 on post-entry steps of ZIKV infection. For this, Vero cells were 
incubated with ZIKV-Nanoluc for 2 h, and then the inoculum was replaced by medium containing FAM E3. The 
data showed that FAM E3 decreased viral replication up to 86% whilst retaining cell viability above 90% (Fig. 2C). 
These data suggest that the antiviral activity of FAM E3 is related to its ability to inhibit a post-entry stage of the 
virus lifecycle, most likely viral RNA replication.
Potential mechanisms of action of FAM E3. To investigate possible mechanisms of action of FAM E3, we 
analyzed the ability of FAM E3 to intercalate into dsRNA, the replication intermediate of all positive-strand RNA 
viruses. Fifteen nanomoles of an in vitro synthesized dsRNA was incubated with FAM E3 or controls (DMSO or 
the well characterized intercalating agent doxorubicin (DOX)) and the obtained RNA/compound complexes were 
analyzed in 1% agarose gel. Densitometry analysis showed that FAM E3 did not intercalate with dsRNA (Fig. 3A).
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As an assay for the RNA-dependent RNA polymerase activity of ZIKV NS5 was not available, we attempted 
to elucidate whether FAM E3 interacts with RNA synthesis carried out by the unrelated bacteriophage SP6 
DNA-dependent RNA polymerase. For this, an in vitro transcription assay using SP6 RNA polymerase was per-
formed in the presence or absence of FAM E3. Reaction products were analyzed using agarose gel electrophoresis and 
densitometry. As shown in Fig. 3B FAM E3 was unable to inhibit synthesis of ZIKV RNAs by SP6 RNA polymerase.
To test whether FAM E3 interfered with the cell lipid metabolism of the host cells. Vero cells infected with 
ZIKV-Nanoluc and treated with FAM E3, DMSO or OLX were fixed and stained with DAPI (to detect nuclear 
DNA), Bodipy to detect lipid droplets and an anti-NS3 antibody. As expected ZIKV infection increased lipid 
droplet accumulation and this was reduced by FAM E3 treatment, However, FAM E3 did not significantly reduce 
lipid droplet accumulation in non-infected Vero cells. Based on this result, the decrease in lipid droplets in 
infected Vero cells treated with FAM E3 is likely a consequence of the inhibition of virus replication, suggesting 
other mechanism of action for FAM E3 (Fig. 4).
FAM E3 is able to bind to and stabilize the ZIKV NS3Hel protein. Molecular docking calculations 
were performed in order to investigate the possible binding mode and the interactions between FAM E3 and 
ZIKV proteins. The proteins NS2B-NS3 protease, NS3 helicase, NS5 methyltransferase and NS5 polymerase, cap-
sid and envelope were selected due to the availability of their experimentally obtained 3D structures in the protein 
data bank (PDB). The two best docking scores were obtained for NS3 helicase (NS3Hel) (−8.7 and −7.8 Kcal·mol-1, 
for RNA and ATP binding sites, respectively) (Figs. 5 and 6). As shown in Fig. 5, FAM E3 is predicted to bind 
into the NS3Hel RNA binding pocket: the carboxylic acid moiety of FAM E3 participating in hydrogen bonding 
interactions with the amino acid residues Arg598, His486 and adenine (A1) (Fig. 5A,B). Moreover, the aromatic 
rings and hydrophobic groups of FAM E3 were predicted to make hydrophobic packing interactions with residues 
Ala264, Ser268, Met536, Leu541, Pro542, Val543, Val599 and Ala605 (Fig. 5A,B).
Figure 1. Inhibitory activity of FAM E3 on ZIKV replication. Schematic representation of ZIKV-Nanoluc that 
continuously expresses the Nanoluciferase reporter (a). Chemical structure of FAM E3 (b). Dose response assay: 
ZIKV-Nanoluc infected cells (MOI 0.1) were treated with FAM E3 at concentrations ranging from 1 to 10 µM 
and virus replication efficiency was evaluated 72 h.p.i. Simultaneously, Vero cells were equally treated with FAM 
E3 and cells viability was measured 72 h later (c). Effective and cytotoxic concentration of 50%: Vero cells were 
treated with increasing concentrations of FAM E3 ranging from 0.10 to 200 µM. ZIKV replication was measured 
by luciferase assay (indicated by ■) and cellular viability measured using an MTT assay (indicated by ●) (d). 
Vero cells were infected with ZIKVBR and treated with FAM E3 at 3 µM and virus replication was accessed 
72 h.p.i. The intracellular virus was titrated by analysing focus- forming units per milliliters (Ffu/mL), DMSO 
and OLX were used as negative and positive controls, respectively (e). Huh-7 or 293 T cell lines were infected 
with ZIKV-Nanoluc and treated with FAM E3 (3 µM) or DMSO (0.1%) for 72 h (f). Mean values of three 
independent experiments each measured in quadruplicate including the standard deviation are shown. P < 0.05 
was considered significant compared to DMSO control.
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FAM E3 was also predicted to bind into the NS3Hel ATP binding pocket (Fig. 6), in this case the carboxylic 
acid moiety of FAM E3 is predicted to form hydrogen bonding interactions with the amino acid residues Gln197, 
Gly199, Lys200 and Thr201. The ether group of FAM E3 can make a hydrogen bond with Gln455 (Fig. 6A,B). It 
is noteworthy that a similar interaction is observed in the crystal structure of NS3Hel, between the Gln455 residue 
and ATP37. Moreover, FAM E3 made hydrophobic interactions with the residues Pro196, Ala235, Ala317 and 
Met414 (Fig. 6A,B).
In order to experimentally validate the results obtained by docking calculations, a thermal stability assay of 
the ZIKV NS3Hel domain was performed by Differential Scanning Fluorimetry (DSF). The thermal denaturation 
curves of NS3Hel in the presence of FAM E3 or non-treated control showed that FAM E3 was able to increase the 
NS3Hel melting temperature (Tm). This data suggests that FAM E3 could bind to and stabilize the NS3Hel protein 
(Fig. 7A). Additionally, a Micro-Scale Thermophoresis assay was carry out to evaluate the affinity of FAM E3 by 
NS3Hel. As observed in Fig. 7B, a sigmoidal slope was obtained, showing that FAM E3 could bind to NS3Hel. A fit-
ting with the Hill function, a Kd of (0,42 ± 0,03) mM was obtained into the in vitro assay, showing a low affinity of 
Figure 2. Effects of FAM E3 on the different stages of the ZIKV replicative cycle. Vero cells were infected with 
ZIKV-Nanoluc at a MOI = 0.5 and simultaneously treated with FAM E3 for 2 h; cells were washed to remove the 
virus and replaced with fresh media. ZIKV replication was measured by Nanoluc activity at 72 h.p.i (a). Vero 
cells were treated with FAM E3 for 2 h. Then, cells were extensively washed and infected with ZIKV-Nanoluc 
at a MOI = 0.5 for 2 h. The inoculum was removed and the cells were washed and replaced with fresh media. 
ZIKV replication was measured by Nanoluc activity at 72 h.p.i. (b). Vero cells were infected with ZIKV-Nanoluc 
at a MOI = 0.5 for 2 h. The virus was removed, cells were washed and added of fresh media containing FAM 
E3. ZIKV replication was measured by Nanoluc activity at 72 h.p.i (c). For all assays, non-infected Vero cells 
were equally treated with FAM E3 and cell viability was measured 72 h later using MTT assay. DMSO was used 
as negative control and OLX as positive control for infectivity inhibition. Mean values of three independent 
experiments each measured in quadruplicate including the standard deviation are shown. P < 0.05 was 
considered significant.
Figure 3. Analysis of FAM E3 intercalation into the viral dsRNA and its interaction with the activity of phage 
SP6 RNA polymerase. Fifteen nanomoles of dsRNA were incubated with the FAM E3 or intercalating controls 
(DMSO) or (DOX) for 45 minutes at room temperature. The reaction products were subjected to 1% agarose 
electrophoresis gel containing Ethidium Bromide followed by densitometry analysis (a). FAM E3 and 5 µg 
of purified pCCI-SP6-ZIKV amplicon was used for in vitro transcription using SP6 RNA polymerase at the 
presence or absence of FAM E3. Reaction products were analysed by agarose gel electrophoresis followed by 
densitometry analysis (b). Results of a representative of three independent reproducible experiments are shown.
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the compound to the protein, in absence of ATP on NTP binding site. Finally, the effect of FAM E3 on the NTPase 
activity of NS3Hel was also investigated by performing an NTPase activity assay using ATP as substrate and ana-
lyzing the amount of phosphate released by the protein in the reaction. FAM E3 did not significantly decrease the 
amount of phosphate released, compared to the non-treated control (Fig. 7C).
Discussion
In this study we evaluated the ability of synthetic diarylamines derived from anthranilic acid (FAMs), designed 
based on their natural scaffolds, to inhibit ZIKV infection. From this screen we selected FAM E3 for further anal-
ysis as it demonstrated the highest level of inhibition against ZIKV. FAM E3 is an intermediary molecule obtained 
during the production of synthetic acridones. The chemical structure of the FAMs is based on two aromatic rings 
Figure 4. FAM E3 interference with the cell lipid metabolism of the host cells. Vero cells were infected with 
ZIKV at MOI = 0.1 and treated with FAM E3 3 µM or DMSO 0.1% or OLX controls for 72 h. Naïve Vero cells 
were treated with DMSO were used as non-infected cells control. After treatment, cells were fixed and nuclei, 
lipid droplets (LDs) and ZIKV NS3 were labeled using DAPI (blue), BODIPY 493/503 (green) and ZIKV 
anti-NS3 antibody (red), respectively. Scale bar 100 nm.
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and one hydrogen atom linked to an amine group38. Our results demonstrated that FAM E3 was able to inhibit 
ZIKV by blocking viral RNA replication, but it had no effect on ZIKV cell entry.
The observed inhibition of ZIKV RNA replication may result from different biological effects of FAM E3, 
including effects on viral RNA polymerase activity, interference with replicase complex formation, and sup-
pression of interaction of viral replicase proteins with host components. Previous studies have shown that acid 
derivative-containing compounds have interfered in the replicative cycle of different virus families. Zanello and 
coworkers showed that N-sulfonyl anthranilic acid derivatives inhibited the replication of DENV by inactivating 
the RNA-dependent RNA polymerase, quinic acid derivatives inhibited the replication of DENV-3 assayed using 
a sub-genomic replicon in RepDV3-Huh 7.5 cells39. Additionally, anthranilic acid derivatives were reported to act 
as allosteric inhibitors by binding to HCV NS5B polymerase and inhibiting viral genome replication40,41.
Antiviral mechanisms of action already described for some compounds are associated with the ability to inter-
act with viral proteins42–44. In the absence of functional ZIKV NS5 RNA polymerase and informed by the observa-
tion that viral RNA polymerases present structural and functional similarities45, we tested whether FAM E3 could 
inhibit the synthesis of ZIKV genomic RNA in vitro by purified bacteriophage SP6 RNA polymerase. However, 
no significant inhibition of viral RNA transcription was observed. This indirect data, together with molecular 
docking results, suggests that the observed replication inhibition was unlikely to be due to the direct inhibition 
of RNA polymerase activity. Similarly, our results demonstrated that FAM E3 did not intercalate with dsRNA, a 
Figure 5. Predicted intermolecular interactions between FAM E3 and the RNA binding site of ZIKV NS3Hel. 
3D structure of the RNA binding site of ZIKV NS3Hel docked with FAM E3, highlighting the main interactions 
between FAM E3 and amino acid residues, through hydrogen bonds (dotted black lines) and hydrophobic 
interactions (transparent green surface) (a). 2D representation of the protein-ligand interactions (b).
Figure 6. Predicted intermolecular interactions between FAM E3 and the ATP binding site of ZIKV NS3Hel. 
3D structure of the ATP binding site of ZIKV NS3Hel docked with FAM E3, highlighting the main interactions 
between FAM E3 and amino acid residues, through hydrogen bonds (dotted black lines) and hydrophobic 
interactions (transparent green surface) (a). 2D representation of the protein-ligand interactions (b).
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mechanism of action described for compounds which inhibit HCV replication, another member of Flaviviridae 
family45,46.
Knowing that host cell lipids provide a replication platform for viruses, including members of genus Flavivirus, 
several studies have shown that the antiviral potential of some compounds is related to their interference to the 
cellular lipid metabolism, and as a consequence prevent viral morphogenesis. We investigated whether FAM E3 
interferes with host cell lipid metabolism which could contribute to inhibition of viral replication. However, the 
results showed that FAM E3 did not interfere in the morphogenesis of lipid droplets (LDs) in non-infected Vero 
cells. In contrast, treatment of ZIKV infected Vero cells with FAM E3 resulted in a reduction in the numbers of 
LDs, although this is likely to be a consequence of its anti-ZIKV activity, decreasing replication levels. Heaton et 
al. showed that the NS3 protein of DENV is responsible for recruitment of fatty acid synthase (FASN) to virus 
replication sites47. Since our results suggested that FAM E3 binds to and stabilizes ZIKV NS3Hel, we speculate that 
this interaction may result in a reduction of lipid recruitment to the virus replicase complex, which interferes in 
viral replication. NS3Hel is a promising target for antiviral drug discovery due to its essential role in the replication 
of the viral genome48. Some examples of helicase inhibitors include ivermectin49,50, suramin51 and benzoxaz-
ole52, which presented activity against both YFV49 and DENV helicases51–53. The Flavivirus helicases possess two 
enzymatic activities: adenosine triphosphatase (ATPase) which provides the chemical energy, and RNA triphos-
phatase (RTPase) that unwinds viral RNA during the replication process37.
In summary, we have shown that the synthetic compound FAM E3 can inhibit ZIKV infection by blocking the 
genome replication stage. Through molecular docking it was possible to predict a possible interaction between 
FAM E3 and the ZIKV NS3 helicase, an essential protein for ZIKV replication. Based on this, the thermal stability 
and the ATPase activity of the helicase domain of ZIKV (NS3Hel) were investigated in vitro and demonstrated 
that FAM E3 could bind to and stabilize NS3Hel. The results may be useful for further development of antiviral 
against ZIKV infection, as well as for a better understanding of how exactly this synthetic compound inhibits 
viral replication.
Material and Methods
Synthesis, purification and structural elucidation of FAM E3. To a mixture of 2-bromo-5-methoxy-
benzoic acid (20.0 mmol) and 4-methoxyaniline (20.0 mmol) in n-pentanol (50 mL) were added 50 mg of copper 
and 3.0 g of K2CO3. The mixture was stirred under reflux for 24 hours and monitored by TLC. After cooling, 
solvent was evaporated under reduced pressure. The powder was solubilized in ethyl acetate (250 mL) followed 
by liquid-liquid extraction with HCl solution 1,0 mol/L (200 mL × 2). Organic phase was washed with deionized 
water (200 mL), dried with Na2SO4 and evaporated under reduced pressure. The crude product was purified by 
column chromatography over silica gel, using a mixture of ethyl acetate and hexane as mobile phase45,54. Structure 
of FAME3 was confirmed by 1H and 13C NMR data analyses. NMR spectra were recorded on Varian INOVA-
500® (11.7 T) spectrometers, operating at 500 MHz for 1H NMR and 126 MHz for 13C NMR. Chemical shifts (δ) 
were referenced to non-deuterated solvent signals. Signal multiplicities were reported as singlet (s), broad singlet 
(brs), doublet (d) and double doublet (dd). Amorphous yellow solid; yield 45%; 1H NMR (500 MHz; DMSO-d6): 
δH = 3.70 (s, 5-OCH3), 3.74 (s, 4′-OCH3), 6.92 (d, J = 2.0 and 9.0, H-3′ and H-5′), 6.97 (d, J = 9.5, H-3), 7.02 (dd, 
Figure 7. FAM E3 activity on NS3Hel. Thermal denaturation curves of NS3Hel and Boltzmann fitting in the 
presence of DMSO (Control) or FAM E3. Tm of NS3Hel obtained after Boltzmann fitting is represented on the 
table (a). MicroScale Thermophoretic analysis of the interaction between FAM E3 and NS3Hel. Data from four 
experiments were normalized to the fraction of bound ligand and averaged. Kd constant was obtained after a 
sigmoidal shape fitting with the Hill function (black continuous line) (b). NTPase activity of ZIKV NS3Hel in the 
presence or absence of FAM E3 and using ATP as substrate (c).
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J = 3.0 and 9.5 Hz, H-4), 7.12 (d, J = 9.0 Hz, H-2′ and H-6′), 7.37 (d, J = 3.0 Hz, H-6), 9.10 (brs, NH). 13C NMR 
(126 MHz; DMSO-d6): δC = 55.2 (4′-OCH3), 55.4 5-OCH3), 112.1 (C-3), 114.3 (C-1), 114.7 (C-3′ and C-5′), 115.2 
(C-6), 122.1 (C-4), 123.7 (C-2′ and C-6′), 134.1 (C-1′), 142.8 (C-2), 150.2 (C-5), 155.4 (C-4′), 169.5 (COOH)45,54.
The compounds were dissolved in dimethyl sulfoxide (DMSO) and stored at −20 °C. Dilutions of the com-
pounds in complete medium were made immediately prior to the experiments to reach a maximum final concen-
tration of 0.1% DMSO. For all the assays performed, control cells were treated with medium added of DMSO at 
the final concentration of 0.1%. Obatoclax (OLX) at 0.125 µM (AdooQ Bioscience) was used as a positive control 
for inhibition of ZIKV infectivity55.
ZIKV construction. The ZIKV-Nanoluciferase (Nanoluc) construct (Fig. 1A) used in these assays was described 
previously34. For maintenance and propagation of the plasmid containing the pCCI-SP6-ZIKV-Nanoluc, the E. coli 
Turbo strain (New England Biolabs) was used.
Complete amplification of the viral genome was performed using a PCR reaction with Phusion High Fidelity 
(Thermo Fisher) enzyme and the designed primers ZIKV-Forward (5′ CG ATT AAG TTG GGT AAC GCC 
AGG GT 3′) and ZIKV-Reverse (5′ T AGA CCC ATG GAT TTC CCC ACA CC 3′). The PCR product containing 
SP6 promoter followed by complete viral cDNA was purified with the DNA clean and concentration kit (Zymo 
Research). In vitro transcription was performed using the RiboMAX™ Large-scale RNA Production Systems kit 
(Promega), as instructed by the manufacturers.
cell culture
Vero cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma–Aldrich) supplemented with 
100 U/mL penicillin (Gibco Life Technologies), 100 mg/mL streptomycin (Gibco Life Technologies), 1% (v/v) 
non-essential amino acids (Gibco Life Technologies) and 10% (v/v) fetal bovine serum (FBS; Hyclone) at 37 °C in 
a humidified 5% CO2 incubator.
Cell viability assay. Cell viability was measured by MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetra-
zolium bromide] (Sigma–Aldrich) method. Vero cells were seeded in a 96-well plate at a density of 1 × 104 cells 
per well and incubated overnight at 37 °C in a humidified 5% CO2 incubator. Drug-containing medium at differ-
ent concentrations was added to the cell culture. After 72 h of incubation at 37 °C, the media was removed and a 
solution containing MTT at the final concentration of 1 mg/mL was added to each well, incubated for 30 min at 
37 °C in a humidified 5% CO2 incubator after which media was replaced with 100 μL of DMSO to solubilize the 
formazan crystals. Absorbance was measured by optical density (OD) of each well at 562 nm, using a spectropho-
tometer. Cell viability was calculated according to the equation (T/C) × 100%, where T and C represent the mean 
optical density of the treated group and vehicle control group, respectively. The cytotoxic concentration of 50% 
(CC50) was calculated using Prism (Graph Pad).
Virus assays. For virus rescue, 8 × 106 Vero cells were electroporated with 10 µg of RNA viral transcript using 
4 mm cuvettes (450 V, 600 µF, two pulses with an interval of 8 seconds). After electroporation, cells were sus-
pended in culture media supplemented with 2% FBS and placed into 25 cm2 cell culture flask and monitored for 
signs of infection during 5 days. At the end of this time, the viral supernatant was collected and stored at −80 °C. 
To determine the viral titer, Vero cells at a density of 3 × 105 per well were seeded in a 6 well plate for 24 h prior to 
infection. Cells were infected with ZIKV-Nanoluc at 10-fold serially dilutions for 2 h at 37 °C. The inoculum was 
removed and the cells were washed with PBS to completely remove the unbound virus followed by addition of cell 
culture media supplemented with 2% FBS and 2% carboxymethyl cellulose (CMC). Infected cells were incubated 
for 5 days at a CO2 incubator at 37 °C. The media was removed and cells were fixed with 4% formaldehyde, stained 
with 0.5% violet crystal and the plaques were counted.
Antiviral assays. For the initial screening of compounds, Vero cells were seeded at density of 1 × 104 cells 
per well into 96-well plates 24 h prior to the infection. ZIKV-Nanoluc at a multiplicity of infection (MOI) of 0.1 
and compounds were simultaneously added to cells. Samples were harvested in Renilla luciferase lysis buffer 
(Promega) at 72 h post-infection (h.p.i.) and virus replication was quantified by measuring Nanoluciferase activ-
ity using the Renilla luciferase Assay System (Promega) (Fig. 1B). The effective concentration of 50% inhibition 
(EC50) was calculated using Prism (Graph Pad). The values of CC50 and EC50 were used to calculate the selectivity 
index (SI = CC50/EC50). 0.1% DMSO and 0.125 µM OLX were used as vehicle and positive controls, respectively.
To evaluate the dose-dependence of the antiviral effect, FAM E3 at concentrations ranging from 1 µM to 
10 µM, and ZIKV-Nanoluc (MOI = 0.1) were added to the cells simultaneously for 72 h. The cells were washed 
with PBS and harvested in Renilla luciferase lysis buffer prior to measurement of luminescence. Cell viability was 
analyzed concomitantly.
The effect of FAM E3 against a wild type ZIKV strain was tested by using the primary clinical isolate of ZIKV 
(provided by the Evandro Chagas Institute in Belém, Pará35) (ZIKVBR). Vero cells were infected with ZIKVBR at 
MOI = 0.1 and treated with FAM E3 3 µM or controls for 72 h. Then, intracellular virus was titrated by analysing 
focus-forming units per milliliters (Ffu/mL).
Time-of-addition assay. To assess the effect of FAM E3 on ZIKV entry to the host cells, inoculum con-
taining ZIKV-Nanoluc (MOI = 0.5) and compounds were simultaneously added to cells (1 × 104) and incubated 
for 2 h at 37 °C. Cells were extensively washed with PBS to completely remove virus and compounds and were 
replaced with fresh media. Samples were harvested in Renilla luciferase lysis buffer (Promega) at 72 h.p.i. and virus 
infectivity was quantified by measuring luciferase activity using the Renilla luciferase Assay System (Promega).
9Scientific RepoRtS |         (2019) 9:17703  | https://doi.org/10.1038/s41598-019-54169-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
Alternatively, cells were infected with ZIKV-Nanoluc (MOI = 0.5) for 2 h, the viral inoculum was completely 
removed by extensive washing with PBS, and compounds were added. The inhibition of ZIKV replication was 
measured by quantifying Renilla luciferase activity 72 h.p.i, as previously described.
Finally, Vero cells at a density of 1 × 104 cell per well were incubated with the compound for 2 h at 37 °C 
in a humidified 5% prior to infection. After incubation, cells were washed extensively and infected with 
ZIKV-Nanoluc (MOI = 0.5) for 2 h. Then, the inoculum was removed, cells were washed to completely remove 
non-endocytosed virus and fresh media was added. At 72 h.p.i cells were analyzed as described above. In all 
Time-of-Addition experiments DMSO and OLX were used as controls as described above.
DsRNA intercalation assay. To investigate whether the compound interacts with the dsRNA, an exper-
iment using the previously described protocol was performed56. Briefly, fifteen nanograms of the dsRNA were 
incubated with 3 µM of FAM E3 at room temperature for 45 min and electrophoresed on a 1% agarose gel prior to 
analysis by densitometry. DMSO and Doxorubicin (DOX) at 100 µM were used as negative and positive control, 
respectively.
SP6 RNA polymerase transcription assay. Assuming that viral RNA polymerases have similar topol-
ogy and functions45,57, we used SP6 RiboMAX ™ Large-scale RNA Production Systems kit (Promega) to evaluate 
the effect of the compound at in vitro RNA transcription. The pCCI-SP6-ZIKV-Nanoluc was used as target with 
the addition of 3 µM FAM E3. Complete amplification and purification of transcripts corresponding to the viral 
genome was performed as per manufacturers instructions. The RNA was quantified, samples were resolved in a 
1% agarose gel, and results were analyzed by densitometry. DMSO was used as control.
NS3Hel cloning, overexpression and purification. The coding region of NS3Hel from the MR766 strain 
was cloned into the expression vector pETTrx-1a/LIC by Cellco Biotec, generating the NS3Hel_ pETTrx-1a/LIC 
expression vector. Rosetta (DE3) E. coli (Novagen) cells were transformed with NS3Hel_ pETTrx-1a/LIC and 
grown in ZYM 5052 autoinduction medium, supplemented with 50 µg.ml-1 kanamycin and 34 µg.ml-1 chloram-
phenicol at 37 °C, until the OD600 reached 0.6. Protein was expressed at 18 °C for 24 h. Cells were harvested by 
centrifugation and cell pellets was resuspended in 20 mM Tris pH 7.0, 500 mM NaCl, 20 mM Imidazole, 10% 
glycerol. Cells were lysed by sonication and cell debris was separated by centrifugation. NS3Hel was purified using 
five steps: a HisTrap HP 5.0 mL with a Ni Sepharose resin (GE Healthcare), a buffer exchanged with Histrap 
Desalting 5 ml (GE Healthcare), a TEV protease cleavage from 6His-TRX-tag, another HisTrap HP 5.0 ml with a 
Ni Sepharose resin (GE Healthcare) and size-exclusion chromatography on a XK 26/1000 Superdex 200 column 
(GE Healthcare) pre-equilibrated in buffer 20 mM Bis-Tris pH 7.0, 500 mM NaCl, 10% glycerol. The final protein 
sample was analyzed in SDS-PAGE 10% to confirm its purity. Concentration was determined spectrophotomet-
rically in a Nanodrop 1000 spectrophotometer (Thermo Scientific).
Thermal stability assay by differential scanning fluorimetry (DSF). To investigate the thermal sta-
bility of helicase domain of ZIKV (NS3Hel), FAM E3 was diluted to 1.25 mM in 100% DMSO (Synth) and Helicase 
in 20 mM Bis-Tris (Sigma), pH7, 500 mM NaCl (Sigma), 10% glycerol. A solution consisting 20 µM Helicase, 5x 
Sypro® Orange (Sigma Aldrich) was prepared and transferred into each well of the 96-well assay plate (Axygen). 
200 μM of FAM E3 was added and an optical adhesive (Hampton) was used to seal the plate. The thermal sta-
bility measurements were performed by monitoring the fluorescence of Sypro® Orange (λexcitation = 490 nm and 
λemission = 575 nm) while the samples were heated from 25 to 74 °C at a rate of 1 °C/min in a conventional quan-
titative PCR instrument Mx3005P. Thermal denaturation curves were obtained using GraphPad Prism 5.0 and 
an approximation through the Boltzmann equation as described by Huynh and Partch58. DMSO was used as 
reference. The experiments were performed in duplicate.
NS3Hel NTPase activity assay by malachite green assay. Assays to evaluate the ATPase activity of the 
NS3Hel were performed using the commercial QuantiChrom™ ATPase/GTPase Assay Kit (BioAssay Systems) as 
described by Cao et al.59. The assay was standardized for NS3Hel as described in the kit manual. Protein was incu-
bated in 20 mM Bis-Tris buffer, pH7, 500 mM NaCl, 10% glycerol previously supplemented with 8.0 mM MgCl2 
(Sigma) in a 96-well plate (Greiner Crystal Clear). FAM E3 at 320 μM in 20 mM Bis-Tris buffer, pH7, 500 mM 
NaCl, 10% glycerol was added into each well to a final concentration of 40 μM in the reaction. The reaction was 
started with ATP (Sigma) at 2.0 mM and incubated for 30 min at 25 °C. Reactions were terminated with the addi-
tion of reagent buffer supplied by the manufacturer and incubated again for 45 min at room temperature before 
absorbance measurement at λ = 620 nm, which is associated with amount of phosphate released due to ATP 
hydrolysis. The tests were performed in duplicates. DMSO (1% vol/vol) was used as reference. The results were 
analyzed and plotted using the GraphPad Prism 5.0 program.
Microscale thermophoresis. Experiments were performed on a Monolith® NT.115 (Nanotemper technol-
ogies). NS3Hel was labelled on cysteine residues with NT-647-Maleimide dye (Nanotemper Technologies) using 
the Monolith NTTM Protein Labeling Kit RED-MALEIMIDE as per manufacturer’s instructions. The concen-
tration of protein indicated for MicroScale Thermophoresis experiments was 40 nM and a serial dilution of FAM 
E3 from 5 mM to 150 nM60. The dissociation constant Kd was obtained by fitting the binding curve with the Hill 
function.
Immunofluorescence assay. For immunofluorescence assay, 2 × 105 Vero cells were grown in 6-well plates 
24 h prior infection. ZIKV-Nanoluc (MOI = 0.1) and compounds were simultaneously added to cells. Naïve Vero 
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cells treated with DMSO were used as non-infected control. Cells were fixed at 72 h.p.i with 4% paraformaldehyde 
and washed with PBS and blocking buffer (BB) containing: 0.1% Triton X-100 (Vetec Labs, BR), 0.2% bovine 
albumin (BSA) and PBS for 30 min. Then, cells were incubated with primary rabbit polyclonal anti-NS3 antibody 
diluted in BB for 1 h. Alexa Fluor 594 conjugated anti-rabbit IgG was used as secondary antibody. Cells were 
washed and labelled for nuclei and lipid droplets (LDs) with DAPI and BODYPI 493/503, respectively. Images 
were analyzed at EVOs cell imaging systems fluorescence microscopy (Thermo Fisher Scientific).
Molecular docking. FAM E3 was docked into six available crystallographic ZIKV protein structures using 
the Autodock Vina 1.1.2 software61. The crystallographic structures of NS2B-NS3 protease (PDB ID: 5H4I)62; NS3 
helicase (PDB ID: 5GJB37, helicase with RNA strand); NS5 methyltransferase (PDB ID: 5KQR)63; NS5 polymerase 
(PDB ID: 5TFR)64, capsid protein (PDB ID: 5YGH)65 and envelope protein (PDB ID: 5LBV)66 were obtained from 
the Protein Data Bank (https://www.rcsb.org). The target proteins were prepared as part of the OpenZika project67 
by using the MolProbity68,69 server to add the hydrogen atoms; the open source version of PyMOL70 was then used 
to align all target models onto a single coordinate reference frame (using the align by alpha carbons command 
line); followed by using AutoDockTools 1.5.671, to format the atom types, calculate Gasteiger-Marsili charges, and 
merge the non-polar hydrogens onto their respective heavy atoms, using the default AutoDockTools preparation 
protocol for proteins, described elsewhere71.
The SMILES structure of FAM E3 was obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). 
Then, the ligand was prepared in the Avogadro software 1.2.072, by adding hydrogen atoms at pH 7.4 and minimiz-
ing the geometry using the MMFF94 force field. The minimized structure was then prepared in AutoDockTools 
1.5.671, following the standard preparation protocol for ligands (allowing full ligand flexibility)71.
The protein grid coordinates were built based on ZIKV protein binding pockets described in the literature: 
NS2B-NS3 protease (pocket of co-crystallized inhibitor boronate73 and ((1H-benzo[d]imidazole-1-yl) methanol))62, 
NS3 helicase (RNA and ATP binding sites), NS5 methyltransferase (Guanosine-5′-triphosphate (GTP), 
S-Adenosyl methionine (SAM) and active), NS5 polymerase (RNA, nucleoside triphosphate (NTP) and active 
site) and E protein (predicted pocket)74. The capsid pockets were predicted using the PockDrug server75: pocket 
1 (between N-terminal - α1 helix of the monomers) and pocket 2 (between α4 helices of the monomers)48. The 
analysis of docking results was based on docking scores, 2D protein-ligand interaction map and visual inspection 
of the docked 3D binding modes. Visual Molecular Dynamics program (VMD)76 was used to render the 3D 
molecular image.
Statistical analysis. Individual experiments were performed in triplicate and all assays were performed 
a minimum of three times in order to confirm the reproducibility of the results. Differences between means of 
readings were compared using analysis of variance (one-way or two-way ANOVA) or Student’s t-test using Graph 
Pad Prism 5.0 software (Graph Pad Software). P values of less than 0.05 (***) were considered to be statistically 
significant.
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